All Articles

On the 14th anniversary of his abduction in Syria, the call to free Austin Tice grows louder, yet the journalist and veteran remains missing.

In a swift 24-hour strike, New York Teamsters secured a landmark deal with a beverage giant, winning not just wages but a crucial foothold against AI.

Vietnam's Viettel Group dominated the 2026 International Business Awards, a stunning victory that confirms its successful pivot from telecom to tech powerhouse.

With billions on the line and major projects moving forward, Canada's CCUS sector is at a crossroads. A pivotal conference in Edmonton will test if policy can fuel profit.

GMO Internet Group's elite hackers conquered the 'Olympics of Hacking.' We explore how this hard-won victory impacts real-world security and the future of AI-driven cyber warfare.

A new coaster and resort are just the start. We dissect how a $150M investment in Ozarks heritage aims to transform a theme park into a national destination.

A beloved brand returns to Maryland’s billion-dollar cannabis market. But is this a story of community or a calculated play for market share?

In a strategic pivot, Skye Bioscience acquires Redx Pharma, creating Fibrx Therapeutics—a new Nasdaq-listed player armed with $125M and a bold plan.

With assets soaring 290% and revenue nearly doubling, PMGC Holdings' pivot to strategic acquisitions in aerospace and tech is paying off spectacularly.

How the Royal Canadian Mint's diversified model, blending global coin contracts with savvy metals trading, is delivering resilience and profit in a volatile Q2.

The Detroit Lions' new VR deal isn't just about cool tech; it's a bold play to rewrite the rules of fan access and sports media rights forever.

Shedding its IT baggage, Vaso Corp's Q2 results reveal a focused, profitable healthcare strategy. Is this the new blueprint for MedTech success?

Reading International posts record post-pandemic profits, fueled by a stellar film slate. But beneath the surface, a surge in short-term debt reveals a high-stakes balancing act.

New preclinical data shows NurExone's ExoPTEN protects vital nerve coatings, providing a biological basis for functional recovery in spinal cord injury models.

Beyond a simple donation, Yili's 150,000-ice cream giveaway in Thailand reveals a masterclass in using localized CSR to build brand loyalty and outmaneuver rivals.

How Madison Global’s top client-voted ranking reveals a winning formula blending high-tech platforms with high-touch service, setting a new standard.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

Diodes Inc. secures a massive, interest-free war chest. While markets flinched at the news, the move reveals a calculated strategy for acquisitions and growth.

As Evaxion prepares its Q2 update, investors watch to see if its AI-Immunology™ platform can deliver the financial and clinical results for long-term value.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.